Abstract: A pharmaceutical composition comprising as active ingredient a racemic, S(-), and R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60% by weight of at least one pentahydric or hexahydric alcohol. Optionally the composition may contain citric acid and magnesium stearate.

Abstract: A joint prosthesis for attachment to a bone of a patient, comprising an anchor with a head surface and a stem for attachment to an end of the bone, the head surface having an anatomically accurate shape.

Abstract: This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammamlian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic said molecule which encodes a human glycine transporter, pharmaceutical compounds r

Abstract: The present invention provides a recombinant fowlpox virus designated S-FPV-043 (ATCC Accession No. VR 2395). A vaccine useful for immunizing an animal against fowlpox virus and Newcastle disease virus is provided which comprises an effective immunizing amount of S-FPV-043 and a suitable carrier. A method of immunizing an animal against fowlpox virus and Newcastle disease virus is also provided which comprises administering to the animal an effective immunizing dose of the vaccine.

Abstract: This invention is directed to tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.

Abstract: A braided wire according to the present invention is constituted by weaving a plurality of first long conductors arranged in parallel and a plurality of second long conductors arranged in parallel so as to cross the first long conductors each other. Each of the first and second long conductors has a section which is perpendicular to an axis thereof and flattened such that a thickness of the conductor is decreased toward both end portions in a width direction. The first and second long conductors each having the flattened section are woven such that they are put one on another in a thickness direction.

Abstract: The present invention provides a hybrid, nonprimate herpesvirus comprising DNA which includes a sequence essential for viral replication of the hybrid, nonprimate herpesvirus, at least a portion of which is present in a sequence essential for replication of a naturally-occurring nonprimate herpesvirus and at least one foreign DNA sequence. Also provided is an attenuated, nonprimate herpesvirus comprising DNA which includes a sequence essential for viral replication of the attenuated, nonprimate herpesvirus, at least a portion of which is present in a sequence essential for replication of a naturally-occurring nonprimate herpesvirus, from which at least a portion of a repeat sequence has been deleted. Also provided are vaccines comprising the viruses of the invention and methods of immunizing animals against various disease.

Abstract: A gas turbine plant having a compressor, gas turbine, and combustor, comprising a cooling system adapted to cool the wall of the combustor by means of air compressed by the combustor when the load of the gas turbine and/or the combustion load of the combustor is low, and an additional cooling system adapted to cool the wall of the combustor by means of a cooling medium different from the air in addition to the cooling by means of the air when the load of the gas turbine is increased.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF1 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to (a) a nucleic acid encoding a human SNORF1 receptor and having a sequence identical to the sequence of the human SNORF1 receptor-encoding nucleic acid contained in plasmid pEXJ-hSNORF1-f (ATCC Accession No. 203898) or (b) a nucleic acid encoding a rat SNORF1 receptor and having a sequence identical to the sequence of the rat SNORF1 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-rSNORF1-f (ATCC Accession No. 203897). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF1 receptor, wherein the human SNORF1 receptor comprises an amino acid sequence identical to the sequence of the human SNORF1 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (Seq. I.D. No. 1).

Abstract: A cell comprising a synthetic non-naturally occurring oligonucleotide compound comprises nucleotides whose sequence defines a conserved catalytic region and nucleotides whose sequence hybridizes with a predetermined target sequence within a MoMLV Psi packaging sequence on the HIV tat sequence. The catalytic region may be derived from a hammerhead ribozyme, a hairpin ribozyme a hepatitis delta ribozyme, an PNAase P ribozyme, a group I intron or a group II intron.

Abstract: This invention provides a hairpin-shaped nucleic acid probe which is capable of forming stable hybrid with target nucleic acid, and a method for detecting nucleic acid containing a sequence complementary to a part of sequence of the probe. After contacting RecA to a hairpin-shaped single strand probe for hybridization, this complex is contacted with a target nucleic acid to form a triplex recombination intermediate using RecA function. After ligating the probe and the target nucleic acid, the target nucleic acid is detected by the label on the probe.

Abstract: The gene expressing the .beta. subunit of human thyroid stimulating hormone has been isolated. The gene has been incorporated into plasmid pBR322. Vectors can be used to transform cells which in turn produce pure .beta. subunits. The .beta. subunits can then be combined with the alpha subunit of human glycoprotein hormones to produce pure thyroid stimulating hormone.

Abstract: When the received symbol is located (FIG. 4) within one of regions G, H, I, L, M, N, Q, R, and S, 2 bits are decided to be most reliable to obtain their soft decision values=0 or 7. As for the remaining 2 bits, a soft decision value=0 to 7 is decided by soft decision in the I- or Q-axis direction. When the received symbol is located within one of regions A, E, U, and Y, all the 4 bits are decided to obtain their soft decision values=0 or 7. When the received symbol is located with one of regions B, C, D, F, J, K, 0, P, T, V, W, and X, 3 bits are decided to be most reliable to obtain their soft decision values=0 or 7. As for the remaining 1 bit, a soft decision value=0 to 7 is obtained by soft decision in the I- or Q-axis direction. A soft decision method that can implement soft decision in multilevel (amplitude and/or phase) modulation and can fully exhibit the correction performance of maximum likelihood coding can be provided.

Abstract: A steel cord according to this invention comprises two core wires and five outer wires each having a diameter larger than that of each core wire and integrally twisted on the core wires, wherein a strand constituted by the five outer wires and the two core wires has an oblong cross-section.

Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4.sup.+ cells which comprise contacting CD4.sup.+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4.sup.+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4.sup.+ cells which comprise contacting CD4.sup.+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4.sup.+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4.sup.+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4.sup.+ cells effective to prevent fusion of HIV-1 to CD4.sup.

Abstract: A genetically modified astrocyte for gene therapy is provided. The genetically modified astrocyte includes one or more stably introduced DNA sequences selected from DNA encoding a selectable marker, DNA encoding a poison pill, and DNA encoding a molecule useful for gene therapy. The genetically modified astrocyte may be produced utilizing plasmids and non-viral transfection methods, as are also provided by the subject invention. Methods for producing and utilizing the genetically modified astrocytes and regulating the engineered products, as well as kits thereof, are further provided.

Abstract: This invention is directed to improved catalytic compounds, hammerhead ribozymes, capable of hybridizing with a target RNA to be cleaved. These improved compounds have optimized stems (X)m*(X)m', loops (X)b and hybridizing arms. The invention is also directed to compositions for enhanced RNA cleavage which comprise a first synthetic non-naturally occurring oligonucleotide compound which comprises nucleotides whose sequence defines a conserved catalytic region and nucleotides whose sequence is capable of hybridizing with a predetermined target sequence and a second synthetic non-naturally occurring oligonucleotide which does not contain the predetermined target sequence and is complementary to at least a portion of the first oligonucleotide compound. The invention is also directed to synthetic non-naturally occurring oligonucleotide compounds embedded in a tRNA. The ribozymes and compositions of the present invention may be used in vitro or in vivo. They may be used as diagnostic or therapeutic agents.

Abstract: The present invention provides a metalloporphyrin catalyst represented by the structure: ##STR1##

Abstract: The subject invention provides a bicyclic aminoimidazole compound, a hydroxyalkyl aminoimidazole compound, a bicyclic pyrrole compound, a hymenin compound, an aldehyde aminoimidazole compound, a ketal aminoimidazole compound, a tricyclic compound, and a tetrahydropurine compound. The subject invention also provides for processes for preparing the compounds.